GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (OSTO:BINV) » Definitions » Cyclically Adjusted FCF per Share

BioInvent International AB (OSTO:BINV) Cyclically Adjusted FCF per Share : kr-7.73 (As of Mar. 2025)


View and export this data going back to 2001. Start your Free Trial

What is BioInvent International AB Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

BioInvent International AB's adjusted free cash flow per share for the three months ended in Mar. 2025 was kr-1.863. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is kr-7.73 for the trailing ten years ended in Mar. 2025.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 17.80% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 15.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of BioInvent International AB was 17.80% per year. The lowest was 14.10% per year. And the median was 14.50% per year.

As of today (2025-05-30), BioInvent International AB's current stock price is kr37.00. BioInvent International AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was kr-7.73. BioInvent International AB's Cyclically Adjusted Price-to-FCF of today is .


BioInvent International AB Cyclically Adjusted FCF per Share Historical Data

The historical data trend for BioInvent International AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioInvent International AB Cyclically Adjusted FCF per Share Chart

BioInvent International AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.40 -14.60 -10.80 -9.72 -8.12

BioInvent International AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.12 -8.55 -8.58 -8.12 -7.73

Competitive Comparison of BioInvent International AB's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, BioInvent International AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioInvent International AB's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioInvent International AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BioInvent International AB's Cyclically Adjusted Price-to-FCF falls into.


;
;

BioInvent International AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioInvent International AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-1.863/132.8245*132.8245
=-1.863

Current CPI (Mar. 2025) = 132.8245.

BioInvent International AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -5.654 99.995 -7.510
201509 -1.846 100.228 -2.446
201512 -1.612 100.276 -2.135
201603 0.221 100.751 0.291
201606 -2.442 101.019 -3.211
201609 -2.407 101.138 -3.161
201612 -2.155 102.022 -2.806
201703 -0.774 102.022 -1.008
201706 -1.942 102.752 -2.510
201709 -2.418 103.279 -3.110
201712 -2.336 103.793 -2.989
201803 -2.309 103.962 -2.950
201806 -2.736 104.875 -3.465
201809 -2.479 105.679 -3.116
201812 -2.665 105.912 -3.342
201903 -2.865 105.886 -3.594
201906 -1.849 106.742 -2.301
201909 -1.179 107.214 -1.461
201912 -1.385 107.766 -1.707
202003 -1.768 106.563 -2.204
202006 -1.447 107.498 -1.788
202009 -1.005 107.635 -1.240
202012 0.701 108.296 0.860
202103 -1.253 108.360 -1.536
202106 -1.127 108.928 -1.374
202109 -1.076 110.338 -1.295
202112 -1.343 112.486 -1.586
202203 -1.414 114.825 -1.636
202206 -1.105 118.384 -1.240
202209 2.640 122.296 2.867
202212 -1.198 126.365 -1.259
202303 -1.246 127.042 -1.303
202306 -1.347 129.407 -1.383
202309 -1.656 130.224 -1.689
202312 -1.145 131.912 -1.153
202403 -1.032 132.205 -1.037
202406 -1.889 132.716 -1.891
202409 -1.507 132.304 -1.513
202412 -1.510 132.987 -1.508
202503 -1.863 132.825 -1.863

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


BioInvent International AB  (OSTO:BINV) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


BioInvent International AB Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of BioInvent International AB's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


BioInvent International AB Business Description

Traded in Other Exchanges
Address
Ideongatan 1, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

BioInvent International AB Headlines